RECHARGEABLE CELL CONTAINMENT DEVICE--PANCREATIC ISLET

维持正常血糖应防止发生；或停止 糖尿病继发并发症的研究进展 外源性胰岛素治疗在产生始终如一、 长期的正常血糖。胰腺组织移植显示出令人鼓舞的结果 结果，但仅限于捐赠器官的短缺，技术上 手术并发症，宿主的免疫反应，以及 所需免疫抑制药物的感染和并发症 心理治疗。生物人工胰腺提供了潜在的解决方案，通过提供 对所含胰岛组织的免疫保护作用。这将允许使用 不需要免疫抑制的异种胰岛组织。这个 PI已经开发出一种细胞封闭装置，已被证明：1) 免疫隔离来自宿主的异种胰岛，2)允许胰岛 产生胰岛素并保持存活长达43天，3)轻松交换 装置内的胰岛不需要手术干预来维持其 功能，4)避免设备的封装。 该第一阶段提案将证明该设备用于 猪胰岛在实现正常血糖的研究犬中的评估 与微囊化胰岛相比，裸露胰岛与微囊化胰岛的使用效率 设备。

The maintenance of euglycemia should prevent the development of; or halt the progression of secondary complications of Diabetes Mellitus. Exogenous insulin therapy has been unsuccessful in producing consistent, long term euglycemia. Pancreatic tissue replacement has shown encouraging results but is limited to date by the shortage of donor organs, technical complications of the surgery, the immune response of the host, and infections and complications of the required immunosuppressive drug therapy. Bioartificial pancreas offer a potential solution by providing immunoprotection to the contained islet tissue. This would allow the use of xenogeneic islet tissue without the need for immunosuppression. The PI has developed a cell containment device which has been shown to: 1) immunoisolate xenogeneic islets from the host, 2) allow the islets to produce insulin and remain viable for up to 43 days, 3) easily exchange islets within the device without surgical intervention to maintain its function, 4) avoid encapsulation of the device. This Phase I proposal will prove feasibility of the device for use with porcine islets in achieving euglycemia in research dogs to assess the efficiency of naked vs. microencapsulated islets when used with this device.